Financial Press Releases
About Avicanna
Strategically positioned to be a front runner in the;
• Development
• Manufacturing and;
• Commercialization of plant-derived cannabinoid-based products
Aug 14, 2019
Avicanna Reports Second Quarter 2019 Financial Results
TORONTO, Aug. 14, 2019 /CNW/ – Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces results for the second quarter …
July 18, 2019
Avicanna Commences Trading on the TSX Under the Symbol "AVCN"
TORONTO, July 18, 2019 /CNW/ – Avicanna Inc. (“Avicanna”) a company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that its common shares …
July 16, 2019
Avicanna Announces TSX Listing Date
TORONTO, July 16, 2019 /CNW/ – Avicanna Inc. (“Avicanna” or the “Company”) a company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce that its common shares (“Common Shares”) are expected to commence trading on the Toronto Stock Exchange (TSX) …
July 10, 2019
Avicanna Announces Receipt for Final Prospectus and Conditional Approval for Listing on the TSX
TORONTO, July 10, 2019 /CNW/ – Avicanna Inc. (“Avicanna” or the “Company“) a company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based …
▪ Avicanna Closes Oversubscribed $22.1 Million Special Warrant Offering
▪ Avicanna Announces Filing of Preliminary Prospectus – January 21, 2019
▪ Avicanna Inc. Acquires 60% Stake in Colombian Medical Marijuana Firm Santa Marta Golden Hemp – August 16, 2018
▪ Avicanna Completes 2nd Equity Financing & Welcomes New Strategic Shareholder – January 29, 2018
▪ Avicanna Closes its First Equity Financing and Announces its Residency at Johnson & Johnson Innovation, JLABS @ Toronto – May 26, 2017
